Inmune Bio, Inc.

8-K · ea0293325-8k_inmune.htm iXBRL

0001711754

 2026-06-02
 2026-06-02

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

 FORM 8-K

  

 CURRENT REPORT

  

 Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

  

 Date of Report (Date of earliest event reported):
 June 2, 2026

  

 INMUNE BIO INC.

 (Exact name of registrant as specified in charter)

  

 Nevada
  
 001-38793
  
 47-5205835

 (State or other jurisdiction
  
 (Commission File Number)
  
 (IRS Employer

 of incorporation)
  
  
  
 Identification No.)

  

 225 NE Mizner Blvd. , Suite 640 , Boca Raton ,
 Florida 33432

 (Address of Principal Executive Offices) (Zip Code)

  

 ( 561 ) 710-0512  

 (Registrant’s Telephone Number, Including
Area Code)

  

 Not Applicable

 (Former Name or Former Address, If Changed Since
Last Report)

  

 Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction
A.2. below):

  

 ☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)

  

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)

  

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))

  

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b)
of the Act:

  

 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 Common Stock, par value $0.001 per shares
  
 INMB
  
 The NASDAQ Stock Market LLC

  

 Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).

  

 Emerging growth company ☐

  

 If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item 8.01. Other Events.

  

 On June 2, 2026, INmune
Bio Inc. issued a press release announcing results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL
Phase 2 clinical trial of XPro™ (XPro1595) in patients with early Alzheimer's disease encompassing both mild cognitive impairment
(MCI) and mild Alzheimer’s disease dementia.

  

 A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  

 Item 9.01 Financial statements and Exhibits

  

 (d) Exhibits.

  

 99.1
  
 Press Release dated June 2, 2026

 104
  
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 1

  

  

 SIGNATURES

  

 Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  
 INMUNE BIO INC.

  
  

 Date: June 2, 2026
 By:
 /s/ David Moss

  
 Name: 
 David Moss

  
 Title:
 Chief Executive Officer

  

  

 2